Answers are grounded in this paper and cite their sources.
Randomized trial estimates treatment effects using covariate adjustment to improve comparability in cluster trials, indicating better metrics across studies.
Standardized mean differences (SMDs) are widely used to quantify treatment effects in cluster‐randomized trials. However, covariate adjustment in hierarchical linear models reduces the residual variance components used for standardization, which artificially inflates effect size estimates and undermines comparability across studies. We propose a unified family of estimators that recover the unadjusted variance components by rescaling the covariate‐adjusted variance components using pseudo‐ indices. This rescaling places effect size estimates on a common reference scale, thereby improving comparability across studies and model specifications under standard modeling assumptions. The framework accommodates three covariate adjustment scenarios including level‐1, level‐2, and simultaneous both‐level adjustments. Furthermore, it introduces three estimator types spanning method of moments, maximum likelihood, and a t ‐statistic reformulation suitable for meta‐analysis from published summaries, alongside delta‐method variance approximations for each. An empirical example and a simulation study apply the proposed covariate‐adjusted SMDs across these scenarios to illustrate their implementation and demonstrate the consequences of omitting the correction.
No takes yet. Share an insight, caveat, or question.
Jung et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: